Arecor Therapeutics PLC (AIM:AREC) CEO Sarah Howell joined Stephen Gunnion with an update on the strong progress the company made in 2021 and details of what lies ahead for 2022.
Howell telling Proactive that the strong momentum continues across its portfolio of owned and partnered assets, as it begins its clinical trial of AT247, an ultra-rapid insulin that will be delivered by continuous subcutaneous infusion via an insulin pump.
She also said investors should also watch out for exciting data due out in the second half of the year.
